Research programme: small molecule therapeutics - Bayer/Dewpoint Therapeutics
Latest Information Update: 28 Dec 2023
At a glance
- Originator Bayer; Dewpoint Therapeutics
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Female genital diseases
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Cardiovascular-disorders in Germany
- 28 Dec 2023 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 28 Dec 2023 No recent reports of development identified for research development in Female-genital-diseases in Germany